Clinical trials: Osteopenia, Generalized
Osteopenia
Heartland Osteoporosis Prevention Study
The purpose of this study is to identify the best way to prevent bone loss in the first years after menopause. The HOPS study will compare bone loss at 12 months in women: 1) who take calcium and vitamin D only; 2) who take…
- Trial name
- HOPS (NCT02186600)
- Testing
- Calcium Carbonate, Vitamin D3, Risedronate
- Where
- United States
- Volunteers
- 276 people
- Sponsor
- University of Nebraska
Osteopenia
A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women
The main purpose of this study is to assess the safety, tolerability and potential immune response to romosozumab following single subcutaneous (SC; injection under the skin) dose administration in healthy postmenopausal Japanese…
- Trial name
- NCT01101061
- Testing
- Romosozumab
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Amgen
Menopause, Fracture
Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Idiopathic osteoporosis (IOP) is an uncommon disorder in which otherwise healthy young individuals sustain one or more low-trauma fractures.
- Conditions
- Menopause, Fracture, Osteoporosis
- Trial name
- IOPForteo (NCT00697463)
- Testing
- Teriparatide (PTH 1-34)
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Columbia University
Osteopenia, Osteoporosis
Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation
This is a Phase 2, open-label, randomized, controlled clinical study of pediatric subjects treated with pamidronate with calcium and vitamin D versus calcium and vitamin D alone following hematopoietic cell transplantation (HCT).
- Trial name
- NCT02074631
- Testing
- Pamidronate, Calcium and vitamin D
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Bone Loss, Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171340
- Testing
- Zoledronic acid, Letrozole
- Where
- 106 sites in Argentina, Australia and 26 more
- Volunteers
- 1,065 people
- Sponsor
- Novartis Pharmaceuticals
Osteopenia
Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women--Aim 2
The wearable vibration device aims to consistently deliver vibrations directly to the hip and spine and allowing use during many everyday activities.
- Trial name
- NCT03688282
- Testing
- Wearable vibration belt
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Theranova, L.L.C.
Menopause, Osteoporosis
Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms
The purpose of this study is to determine if soy-derived phytoestrogens (naturally occurring compounds similar to estrogen) can prevent bone loss and other menopausal symptoms in women who have recently gone through menopause.
- Conditions
- Menopause, Osteoporosis, Osteopenia
- Trial name
- SPARE (NCT00076050)
- Testing
- Soy isoflavones
- Where
- United States
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- University of Miami
Anorexia Nervosa, Osteopenia
Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa
Decreased bone strength is a serious medical problem present in many women with Anorexia Nervosa, or disordered eating. Women with weaker bones are more likely to suffer broken bones than women with normal bone strength.
- Conditions
- Anorexia Nervosa, Osteopenia, Osteoporosis, Eating Disorders
- Trial name
- NCT00283595
- Testing
- Recombinant Human Growth Hormone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Osteoporosis, Chronic Kidney Disease
Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
The primary objective of the study is to examine the effect of denosumab on lumbar spine bone mineral density (BMD) after one year of treatment in newly transplanted renal allograft recipients.
- Trial name
- POSTOP (NCT01377467)
- Testing
- Denosumab (Prolia)
- Where
- Switzerland
- Volunteers
- 90 people
- Sponsor
- Rudolf Wuethrich
Post-Menopausal Osteopenia
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
This 2 arm study will evaluate the efficacy and safety of oral Bonviva 150mg once monthly compared with placebo in post-menopausal women with osteopenia.
- Trial name
- NCT00129623
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 12 sites in United States
- Volunteers
- 160 people
- Sponsor
- Hoffmann-La Roche
Low Bone Mass, Low Bone Mineral Density
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
The purpose of this study is to assess how effective and safe denosumab is in a population of males with low bone mass at risk of fracture.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Males With Osteoporosis, Osteopenia
- Trial name
- NCT00980174
- Testing
- 60 mg denosumab
- Volunteers
- 242 people
- Sponsor
- Amgen
Osteopenia
A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis
The primary purpose of this study was to evaluate the efficacy of oral calcitonin (rsCT)tablets in the prevention of bone loss in postmenopausal women with lower bone mineral density at increased risk of fracture.
- Trial name
- NCT01292187
- Testing
- Oral calcitonin at dinnertime, Oral calcitonin at bedtime
- Where
- 10 sites in United States
- Volunteers
- 129 people
- Sponsor
- Tarsa Therapeutics, Inc.
Bone Diseases, Metabolic, Osteoporosis, Postmenopausal
The Effects of Potassium Citrate on Bone Metabolism
Skeletal buffering of chronic acid loads may contribute to a significant amount of bone loss over time. Evidence from a few small short-term studies suggests that basic compounds, namely potassium citrate and potassium…
- Trial name
- NCT00357331
- Testing
- potassium citrate
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Osteoporosis
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
The aim of this study was to examine the effect of zoledronic acid and alendronate on bone metabolism as measured by biomarkers in postmenopausal women with osteoporosis.
- Trial name
- ROSE (NCT00404820)
- Testing
- Zoledronic acid 5 mg solution, Alendronate 70 mg tablets, Calcium/Vitamin D
- Where
- Germany
- Volunteers
- 604 people
- Sponsor
- Novartis
Osteoporosis, Bone Loss
Romosozumab in Women With Chronic SCI
This two-year open-label pilot clinical trial will evaluate the efficacy and safety of romosozumab to treat bone loss in females with chronic spinal cord injury (SCI) and osteoporosis (OP).
- Conditions
- Osteoporosis, Bone Loss, Osteopenia, Osteoporosis, Spinal Cord Injuries
- Trial name
- NCT04708886
- Testing
- Romosozumab, Alendronate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
HIV, Osteopenia
Switch From Tenofovir to Raltegravir for Low Bone Mineral Density
The purpose of this study is to determine if low bone mineral density (a measurement of how thick and strong bones are) improves in adults with HIV infection who switch their HIV medication tenofovir to another HIV medication…
- Conditions
- HIV, Osteopenia, Osteoporosis, HIV Infections
- Trial name
- TROP (NCT00939874)
- Testing
- Raltegravir
- Where
- 4 sites in Australia
- Volunteers
- 52 people
- Sponsor
- St Vincent's Hospital, Sydney
Adult Idiopathic Generalized Osteoporosis
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
The purpose of this research study is to evaluate antiresorptive therapy with denosumab (Prolia) for prevention of bone loss after stopping teriparatide (TPTD) in premenopausal women with idiopathic osteoporosis.
- Trial name
- NCT02049866
- Testing
- Denosumab
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Elizabeth Shane
Breast Cancer, Low Bone Mineral Density
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
- Conditions
- Breast Cancer, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00089661
- Testing
- AMG 162 / Denosumab
- Volunteers
- 252 people
- Sponsor
- Amgen
Osteopenia, Arterial Hypertension
Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women
This study evaluates the effect of moxonidine versus bisoprolol on collagen type 1 C-telopeptide in postmenopausal female patients with arterial hypertension and osteopenia.
- Trial name
- COMPASS (NCT02355821)
- Testing
- Moxonidine, Bisoprolol
- Where
- Russia
- Volunteers
- 114 people
- Sponsor
- National Research Center for Preventive Medicine
Osteopenia
A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass
The purpose of this study is to evaluate the effect of romosozumab on parameters of bone quality of the forearm using peripheral quantitative computed tomography (pQCT) following multiple subcutaneous dose administrations of…
- Trial name
- NCT00950950
- Testing
- Romosozumab
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amgen